Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Dasatinib × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

OTHER 14 NIH 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 42 Myeloid 22 Lymphoid 5 Breast 4 Tumor-Agnostic 3 Genitourinary 3 Plasma cell 2 Gastrointestinal 1 CNS 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 266 Fluorouracil 253 Oxaliplatin 233 Bevacizumab 233 Capecitabine 201 Leucovorin 196 pembrolizumab 194 Irinotecan 161 Cisplatin 132 Cetuximab 122 Nivolumab 117 Paclitaxel 100 130-nm albumin-bound paclitaxel 98 Sorafenib 76 Albumin-Bound Paclitaxel 62 Docetaxel 58 atezolizumab 57 Folfox protocol 55 IFL protocol 53 regorafenib 50 durvalumab 42 Trastuzumab 42 Ramucirumab 40 Panitumumab 40 Sunitinib 38 Injections 37 Drug Therapy 37 Carboplatin 36 lenvatinib 34 tislelizumab 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01395017 2016-04-08

LAPC

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2 Completed

202 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡